INTRODUCTION
Cells of the monocyte/macrophage lineage are among the first to be infected by the human immunodeficiency virus (HIV), and they serve as virus reservoirs during all stages of infection. [1] [2] [3] [4] [5] During the late stages of the disease, when the pool of CD4 + T lymphocytes is significantly depleted, tissue macrophages may become the principal source of the emerging HIV-1. 6 Late stages of AIDS are characterized by profound immune deficiency and development of opportunistic infections. Since the major cellular targets for many microbial pathogens, such as Mycobacterium tuberculosis and Toxoplasma gondii are macrophages, it is of paramount clinical importance to understand the effect of bacterial components on HIV-1 infection of these cells.
Bacterial lipopolysaccharide (LPS), the main constituent of the outer leaflet of the cell wall of Gram-negative bacteria, 7 is a major stimulus for macrophages. LPS treatment activates several transcription factors, including NF-κB, which in turn stimulate expression of HIV-1 provirus. 8, 9 On the other hand, LPS has been shown to protect primary macrophages from de novo infection by HIV-1 in vitro. [10] [11] [12] [13] [14] When LPS was applied to macrophages prior to infection, its protective effect could be attributed to stimulation of secretion of β-chemokines, 12 which are potent inhibitors of virus entry, and to direct down-regulation of CCR5, 14 the main HIV-1 co-receptor on these cells. It should be noted that the effect of LPS stimulation differs between mature differentiated monocyte-derived macrophages (MDM) and freshly isolated monocytes. The latter were shown to become more susceptible to HIV-1 infection when treated with LPS during the differentiation stage. 15 Recently, we demonstrated that addition of LPS to MDM together or even after inoculation with HIV-1 results in suppression of HIV-1 replication. 13 Since these results suggested that LPS can affect HIV-1 replication at a post-entry level, we set up a study to identify the mechanisms responsible for this activity. Results of this study are described in this report and suggest that LPS stimulates entry and rapid degradation of incoming viral particles.
The bacterial endotoxin LPS is a potent stimulator of monocyte and macrophage activation and has been shown to protect differentiated macrophages from de novo infection by HIV-1. However, the mechanisms of this inhibitory activity of LPS are not fully understood. We investigated the effect of LPS on the early post-binding steps of HIV-1 replication in primary macrophages. Paradoxically, when applied together with the virus, LPS stimulated entry of HIV-1 into macrophages, as judged by the amount of internalized HIV-1 RNA and p24. This stimulatory activity did not depend on receptors used for entry and did not require new protein synthesis. However, internalized viral RNA and p24 were rapidly degraded in LPS-stimulated macrophages. Surprisingly, while degradation of HIV-1 p24 in LPS-treated cells was inhibited by bafilomycin A1, HIV-1 RNA was not protected by this agent, suggesting that viral RNA is degraded by a pH-independent mechanism. These results indicate that LPS stimulates both virus uptake and virus degradation in macrophages.
MATERIALS AND METHODS

Cells and reagents
Monocyte-derived macrophages (MDMs) were prepared from blood monocytes by adherence to plastic, as described previously. 13 LPS (Escherichia coli O111:B4) and AZT were purchased from Sigma (St Louis, MO, USA). Cycloheximide, bafilomycin A1, SB203580 and SB202474 were from Calbiochem (San Diego, CA, USA).
Cell viability assay
A 7 mg/ml solution of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide from Sigma) was freshly prepared and filtered. Cells were incubated with MTT (0.7 mg/ml) for 3 h at 37°C, washed and resuspended in isopropanol-HCl solution. Optical density was read on an ELISA plate reader at 570 nm and reflects the amount of metabolized MTT.
Protein and p24 assays
Protein concentration was measured with the Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA), according to the protocol supplied with the kit. Serial dilutions of BSA were used to create the standard curve. p24 was analyzed by an ELISA kit (NEN Life Sciences Products, Inc., Boston, MA, USA).
Infection of MDM
Cells (1 x 10 6 cells/well) were inoculated with M-tropic HIV-1 ADA virus (10 ng of p24 per 10 6 cells) treated with 20 U/ml of RNase-free DNaseI (Roche Diagnostics Corp., Indianapolis, IN, USA) for 1 h at room temperature. Cells were incubated for 1 h on ice, then placed at 37°C for 2 h, washed 3 times with PBS, treated with trypsin (0.025% for 30 min at 37°C), and either collected for analysis or incubated for additional intervals in fresh medium.
Single-round replication assay
Pseudotyped luciferase reporter viruses were produced by co-transfection of 293T cells with plasmids expressing envelope-deficient NL4-3 construct and viral envelopes derived from the amphotropic murine leukemia virus (MuLV) or vesicular stomatitis virus (VSV-G). Cells were inoculated with pseudotyped viruses (5 ng of p24 per 10 6 cells) in the presence or absence of LPS (100 ng/ml) and incubated for 2 h at 37°C, then washed, and incubation was continued in fresh medium without LPS. After 4 days, cells were washed, lysed in reporter lysis buffer (Promega, Madison, WI, USA), and luciferase activity was measured in relative light units using a Dynex MLX microplate luminometer.
Analysis of internalized HIV-1 RNA
Total cellular RNA was extracted using RNAzol B (TEL-TEST, Inc., Friendswood, TX, USA). For each sample, 0.5 mg of RNA was reverse transcribed by M-MLV reverse transcriptase using random hexamers as primers (Gibco BRL, Grand Island, NY, USA). PCR reaction was performed using pol -(for HIV-1 RNA) and β-actin-specific primers exactly as described previously. 16 Following Southern hybridization, results were analyzed on a Phosphorimager and adjusted according to β-actin signal.
RESULTS
To investigate at which step(s) in the replication of HIV-1 in differentiated MDMs LPS exerts its activity, we used a single-round virus replication assay with luciferase-expressing replication-incompetent HIV-1 recombinant virions pseudotyped by envelopes from different viruses, including the macrophage-tropic HIV-1 strain ADA, the amphotropic murine leukemia virus (MuLV), and the vesicular stomatitis virus (VSV). 17, 18 This assay monitors cumulative efficiency of viral attachment, fusion/entry, nuclear transport, integration and transcription. Similar to HIV-1, MuLV enters cells by pH-independent fusion at the plasma membrane; however, this fusion does not depend on HIV-1 receptors CD4 and CCR5. VSV is internalized through receptormediated endocytosis and enters target cells by fusing with the endosomal membrane. Therefore, infection by these pseudotyped viruses should not be affected by the effect of LPS on expression of HIV-1 receptors. LPS potently inhibited infection by all HIV-1 constructs, as measured by luciferase activity in cell lysates ( Fig. 1 ). Analysis of cell viability by an MTT assay did not reveal any toxicity associated with LPS treatment. The percent of inhibition appears to be somewhat smaller for the VSV-G-pseudotyped virus (~35% luciferase activity is detected in LPS-treated relative to untreated cells) than for the two other constructs (less than 10% luciferase activity remains in cells infected with MuLV Env-or HIV-1 ADA Env-pseudotyped viruses), suggesting that a certain component of the LPS inhibitory activity might specifically affect viruses that initiate productive infection by fusing with the plasma membrane. A possible mechanism for this activity is that LPS, through stimulating endocytosis, enhances viral entry via endosomes (a non-productive pathway) at the expense of pH-independent membrane fusion, thus diminishing the amount of replication-competent virus. 19 Taken together, results of this experiment strongly support the notion that in addition to its effect on HIV-1 receptor expression, 14 LPS also inhibits HIV-1 replication independently of the mode of entry, presumably at a post-entry step.
To begin examining the mechanisms of this post-entry inhibition by LPS, we analyzed the effect of LPS on degradation of internalized HIV-1 RNA. To prevent new rounds of infection and RNA degradation by viral reverse transcriptase-associated RNAseH, this experiment was performed in the presence of AZT (10 µM), which completely blocked reverse transcription and virus replication. After inoculation with DNase-treated (to eliminate contaminating HIV-1 DNA) HIV-1 ADA in the presence or absence of LPS, cells were incubated with the virus for 1 h at 4°C to allow absorption and then washed to remove unbound virus. After transfer to 37°C in fresh AZT-supplemented medium with or without LPS, cells were incubated for another 2 h. At the end of this incubation, cells were trypsinized to remove residual non-internalized virus that might have remained bound to cells after washing, and an aliquot was withdrawn for analysis. Remaining cells were washed again, and incubation was continued in AZT-supplemented fresh medium without LPS for an additional 10 h. HIV-1 RNA was analyzed by a coupled RT-PCR using primers specific for the pol region of the viral genome. 20 Given that LPS had an inhibitory effect on HIV-1 infection ( Fig. 1) , it was unexpected that 2 h after absorption, more HIV-1 RNA was detected in LPS-treated cells than in control macrophages ( Fig. 2A) . Importantly, this effect could not be due to LPS-mediated enhancement of fusion efficiency LPS stimulates HIV-1 entry and degradation in human macrophages 273 pretreated with AZT (10 µM) and inoculated with HIV-1 ADA in the presence or absence of LPS (100 ng/ml). Following a 1 h absorption at 4°C, cells were collected, washed and divided into two aliquots. One aliquot was lysed and analyzed by p24 ELISA to evaluate the amount of bound HIV-1 (4°C samples). The other aliquot was transferred to 37°C and incubated for an additional 2 h in the presence or absence of LPS. At the end of incubation, cells were trypsinized, lysed, and the lysate was analyzed by p24 ELISA for the amount of internalized virus (37°C samples). All results were adjusted according to the amount of protein in each sample. Results are presented as percentage of control. The error bars show the range relative to the mean value. Three independent experiments with similar results have been performed.
A B
as flow-cytometric analysis of CD4 and CCR5 expression on cells treated with LPS at 4°C did not reveal any changes in comparison to untreated cells (not shown). In addition, unbound virus was washed away after absorption at 4°C, and treatment of the cells with LPS at 4°C did not affect virus attachment (Fig. 2B ). This increase in RNA uptake by LPS-activated macrophages may be explained by stimulation of the endocytic pathway, which has been shown recently to provide an alternative route for HIV-1 entry. 19 The stimulatory effect of LPS on HIV-1 internalization was confirmed by analysis of cell-associated p24 (Fig.  2B ). This experiment was performed exactly as the one in Figure 2A , except that internalized p24, rather than HIV-1 RNA, was measured by ELISA at 2 h after absorption. Results in Figure 2B demonstrate an approximately 2-fold increase of internalized p24 in LPS-stimulated cells, consistent with the observed effect of LPS on HIV-1 RNA internalization ( Fig. 2A) . However, when analyzed at a later time point (12 or 18 h after absorption), the amount of internalized viral RNA or p24 was similar in LPS-treated and untreated cells (Figs 2A & 3) . This result suggested that LPS treatment stimulated degradation of virionderived nucleoprotein complexes. We have previously hypothesized 13 that in LPS-treated MDMs, the HIV-1 nucleoprotein (pre-integration) complexes might be internalized via phagocytosis/endocytosis and targeted to lysosomes for rapid degradation. To investigate this possibility, we treated cells with a lysosomotropic agent, bafilomycin A1, which inhibits vacuolar type H + -ATPase (V-ATPase) and thus blocks endocytic pathway and degradation. Contrary to our expectations, pretreatment of macrophages with bafilomycin A1 did not alter the effect of LPS on HIV-1 RNA stability (Fig. 3A, compare 2 h p.i. and 18 h p.i. time points). However, this lysosomotropic agent protected internalized p24 from degradation in LPStreated cells (Fig. 3B) . Importantly, bafilomycin A1 did not prevent degradation of p24 in LPS-untreated cells. No bafilomycin A1-induced cytotoxicity was revealed by MTT assay. This result supports the hypothesis that in contrast to normal infection through pH-independent fusion, virus can enter LPS-treated macrophages through phagocytosis/endocytosis, and suggests that degradation of the HIV-1 RNA in LPS-treated macrophages does not require simultaneous degradation of viral proteins.
Stimulation of macrophages with LPS leads to activation of multiple signaling pathways and results in rapid secretion of biologically active molecules. 21 To determine whether production of soluble factors is required for the activity of LPS in HIV-1 infection, we used an inhibitor of protein synthesis, cycloheximide. Results presented in Figure 4 demonstrate that treatment of the MDMs with cycloheximide (50 µg/ml) did not alter the effect of LPS on HIV-1 internalization or degradation. This concentration of cycloheximide completely blocked protein synthesis, as evidenced by inhibition of TNF-α production (not shown). Again, no cycloheximide-specific cytotoxicity was detected by an MTT assay. While a possibility that production of some soluble factor was not fully inhibited by cycloheximide treatment cannot be discounted, this result strongly suggests that the observed activity of LPS was not mediated by a secreted intermediate, but rather was a direct result of signaling activity.
274 Pushkarsky, Dubrovsky, Bukrinsky Fig. 3 . Bafilomycin A1 protects p24, but not HIV-1 RNA, from degradation in LPS-treated MDMs. MDM cultures (two wells per time point/treatment) were pretreated for 1 h with AZT (10 µM) with or without a lysosomotropic agent bafilomycin A1 (1 µM) and infected with HIV-1 ADA in the absence or presence of LPS (100 ng/ml). After a 2 h incubation at 37°C, all cells were washed and trypsinized. Some cells were collected for analysis, the rest were incubated for an additional 16 h in fresh medium containing AZT with or without bafilomycin A1 (no LPS was present during this time). Intracellular HIV-1 RNA or p24 were analyzed by RT-PCR or p24 ELISA, respectively, at indicated time points post inoculation (p.i.), as described in the caption to Figure 2 . Results are presented relative to the amount of HIV-1 RNA or p24 in a 2 h p.i. bafilomycin-untreated (control) sample (taken as 100%). Error bars show the range relative to the mean value. One representative experiment of two performed is shown.
DISCUSSION
HIV variants isolated from patients in early stages of disease are almost exclusively macrophage-tropic strains that use CCR5 co-receptor for entry. However, as disease progresses, the virus loses its capability to replicate efficiently in macrophages. Strains isolated from patients with latestage disease often use CXCR4 as a co-receptor. 17, 22 This late stage of AIDS progression is almost always accompanied by various opportunistic bacterial infections, including infections by Gram-negative bacteria. 23, 24 This study demonstrates that a Gram-negative bacterial wall constituent, LPS, inhibits HIV-1 infection of macrophages and suggests that opportunistic infections may protect macrophages from HIV infection and thus contribute to the observed switch in viral tropism. There is some discrepancy in published reports on the effects of LPS on HIV-1 infection of macrophages. Several studies have shown that LPS enhances HIV replication in monocytoid cell lines and macrophages; 9, 15 however, other reports, including those from our laboratory, have demonstrated the induction of resistance of macrophages to HIV infection upon LPS stimulation. 10, [12] [13] [14] One reason for this discrepancy is differences in macrophage propagation and time of LPS treatment. Indeed, in a recent study by Moriuchi and colleagues describing the enhancing effect of LPS, 15 endotoxin was added to monocytes and was present during the whole in vitro differentiation process. Cells produced as a result of such treatment most likely differ from normally differentiated cells. In contrast, in studies where the inhibitory activity of LPS on HIV infection was observed, LPS was added to already differentiated macrophages.
The enhancing effect of LPS on HIV LTR-directed transcription and expression of integrated provirus described in several studies performed on monocytoid cell lines 8, 9 may operate in macrophages as well. However, it is masked by a potent inhibitory activity exerted at a stage preceding integration. One mechanism of this inhibitory activity is secretion by LPS-stimulated macrophages of β-chemokines, MIP-1α, MIP-1β, and RANTES, which are natural ligands of HIV-1 co-receptor CCR5 and inhibit entry of macrophage-tropic strains. 12 LPS also directly down-regulates CCR5 expression on macrophages, independently of β-chemokine production. 14 In addition, LPS inhibits a postentry step of HIV replication (this report and Zybarth et al. 13 ). This study demonstrates that one mechanism of this post-entry inhibition by LPS is stimulation of degradation of viral nucleoprotein complexes. It appears that LPS treatment activates viral uptake by endocytosis, thus targeting the incoming nucleoprotein complexes for degradation. Such a mechanism is consistent with LPS-induced internalization of CCR5, 14 except that the complex of receptor with bound virus may be internalized. Because LPS-induced internalization of CCR5 is a very rapid and efficient process, it might explain enhanced virus entry into LPS-treated macrophages compared to infection of untreated cells (this report and Zybarth et al. 13 ). Our results showing that bafilomycin A1 treatment prevents degradation of p24 but not of viral RNA suggests that in addition to pH-dependent degradation in lysosomes, virus entering into LPS-treated macrophages might be degraded by a pH-independent mechanism. Still, this degradation should occur within some subcellular compartment, rather than in the cytosol, as earlier studies demonstrated that LPS increases the half-life of cellular mRNAs 25 and thus would be expected to stabilize cytoplasmic viral RNA. Interestingly, despite a more rapid HIV RNA degradation in LPS-treated MDMs than in untreated cells, the amount of residual RNA is not that different in these two systems. One possible explanation is that in addition to virus entry through LPS-mediated endocytosis, the virus can also enter into LPS-treated macrophages via normal pH-independent fusion with the plasma membrane. Viral nucleoprotein complexes entering via the latter pathway are not subject to increased degradation, thus allowing the virus to escape this inhibitory effect of LPS.
The LPS-induced activities described in this report do not require protein synthesis, and thus are most likely directly stimulated by LPS-specific signaling events. Our preliminary results suggest involvement of p38 MAPK-dependent pathway (Pushkarsky T., unpublished observation). Further experiments will be necessary to determine the signal transduction pathway regulating the observed activities of LPS.
CONCLUSIONS
In summary, our results suggest that treatment of MDMs with LPS stimulates HIV-1 entry by endocytosis. This pathway leads to rapid degradation of incoming virus, both LPS stimulates HIV-1 entry and degradation in human macrophages 275 Fig. 4 . LPS effects do not require protein synthesis. The experiment was performed exactly as described in the caption to Figure 3 , except that an inhibitor of protein synthesis cycloheximide (50 µg/ml) was used instead of bafilomycin A1. by pH-dependent and pH-independent mechanisms and outside of lysosomal compartment. However, enhanced degradation of the viral nucleoprotein complex cannot account for the whole inhibitory activity of LPS. Indeed, less than 10% of luciferase activity can be detected in LPS-treated relative to untreated cells infected with luciferase-expressing HIV-1 (Fig. 1) , while more than 25% of viral RNA remains in HIV-1-infected cells even after 18 h (Figs 3 & 4) . This result suggests that additional mechanisms restricting maturation of the remaining viral RNA must be involved in LPS-treated macrophages. One such mechanism proposed in our previous report 13 is inhibition by LPS of nuclear import of the HIV-1 pre-integration complexes in macrophages. Further studies are required to define that mechanism.
